Dupilumab Study for Pruritus of Lichen Simplex Chronicus in Adults in NYC
ENROLLING — This Phase 3, 2-arm study evaluates pruritus improvement with dupilumab injections versus placebo in adults with LSC.
ESK-001 for Moderate to Severe Plaque Psoriasis Study in Kentucky (ONWARD1)
ENROLLING — This clinical trial will evaluate the effectiveness of ESK-001 in treating moderate to severe plaque psoriasis.
Ruxolitinib Cream Study for Pediatric Nonsegmental Vitiligo in NYC
ENROLLING — This study evaluates the safety and efficacy of Ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Ruxolitinib Cream Study for Pediatric Nonsegmental Vitiligo in Kentucky
ENROLLING — This study evaluates the safety and efficacy of Ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
APG777 for Moderate to Severe Atopic Dermatitis Study in NYC
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
APG777 for Moderate to Severe Atopic Dermatitis Study in Kentucky
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in NYC
ENROLLING — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in Kentucky
ENROLLING — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Upadacitinib for Moderate to Severe Hidradenitis Suppurativa Study in Kentucky
ENROLLING — This study will assess how safe and effective Upadacitinib is in treating adult and adolescent participants with moderate to severe HS.
Ixekizumab and Tirzepatide for Plaque Psoriasis and Overweight Study in NYC
ENROLLING — Be part of our NYC study to explore the effects of Ixekizumab and Tirzepatide on individuals with plaque psoriasis and overweight.